Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEGONIA: Durvalumab Combinations in First-line Metastatic Triple Negative Breast Cancer
NCT03742102Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Dec 2018
- Primary completion
- Nov 2024
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 6
01
Overview
Phase 2, open-label trial of durvalumab in triple-negative breast cancer (TNBC) (6 arms), sponsored by AstraZeneca. Primary endpoint: Dose Limiting Toxicity Events at 28 days. Started Dec 2018; status: active, not recruiting.
02
Drugs
durvalumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03742102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03742102.